Kiromic Biopharma Inc (KRBP) — Cash Flow-to-Debt Ratio

Latest as of December 2024: -0.17x

Kiromic Biopharma Inc (KRBP) has a Cash Flow-to-Debt Ratio of -0.17x as of December 2024, meaning its operating cash flow of $-3.65 Million could theoretically repay 0% of its total liabilities ($21.13 Million) in one year. See how liquid is Kiromic Biopharma Inc's working capital to evaluate short-term liquidity relative to the company's equity base.

CF-to-Debt Ratio

-0.17x
Operating CF / Total Liabilities

Operating Cash Flow

$-3.65 Million
USD

Total Liabilities

$21.13 Million
USD

Data as of

Dec 2024
Most recent filing

Kiromic Biopharma Inc Cash Flow-to-Debt Ratio (2018–2024)

Historical debt coverage capacity for Kiromic Biopharma Inc across 7 annual periods. Also explore net asset growth rate of Kiromic Biopharma Inc to track the company's year-over-year net asset growth rate.

Annual Cash Flow-to-Debt Ratio for Kiromic Biopharma Inc (2018–2024)

Year-by-year debt coverage analysis for Kiromic Biopharma Inc. For market capitalisation and broader financial context, see market value of Kiromic Biopharma Inc.

Year CF-to-Debt Ratio Operating CF (USD) Total Liabilities YoY Change
2024 -0.92x $-19.46 Million $21.13 Million ▲ +7.6%
2023 -1.00x $-21.23 Million $21.29 Million ▲ +25.5%
2022 -1.34x $-23.75 Million $17.74 Million ▲ +77.5%
2021 -5.96x $-20.32 Million $3.41 Million ▼ -42.8%
2020 -4.17x $-6.13 Million $1.47 Million ▲ +3.5%
2019 -4.33x $-2.91 Million $673.70K ▼ -22.7%
2018 -3.53x $-2.15 Million $610.70K
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.